Established and New Rotavirus Vaccines: a Comprehensive Review for Healthcare Professionals

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2021 Feb 19

PMID 33605839

Citations 12

Authors

Volker Vetter

Robert C Gardner

Serge Debrus

Bernd Benninghoff

Priya Pereira

Affiliations

Soon will be listed here.

Abstract

Robust scientific evidence related to two rotavirus (RV) vaccines available worldwide demonstrates their significant impact on RV disease burden. Improving RV vaccination coverage may result in better RV disease control. To make RV vaccination accessible to all eligible children worldwide and improve vaccine effectiveness in high-mortality settings, research into new RV vaccines continues. Although current and in-development RV vaccines differ in vaccine design, their common goal is the reduction of RV disease risk in children <5 years old for whom disease burden is the most significant. Given the range of RV vaccines available, informed decision-making is essential regarding the choice of vaccine for immunization. This review aims to describe the landscape of current and new RV vaccines, providing context for the assessment of their similarities and differences. As data for new vaccines are limited, future investigations will be required to evaluate their performance/added value in a real-world setting.

Citing Articles

Biotechnological Interventions for the Production of Subunit Vaccines Against Group A Rotavirus.

Prajapati M, Malik P, Sinha A, Yadav H, Jaiwal Y, Ahlawat Y Cell Biochem Funct. 2024; 42(8):e70031.

PMID: 39707603 PMC: 11662099. DOI: 10.1002/cbf.70031.

Mannose and Lactobionic Acid in Nasal Vaccination: Enhancing Antigen Delivery via C-Type Lectin Receptors.

Colaco M, Cruz M, de Almeida L, Borges O Pharmaceutics. 2024; 16(10).

PMID: 39458637 PMC: 11510408. DOI: 10.3390/pharmaceutics16101308.

Molecular Design of Encapsulin Protein Nanoparticles to Display Rotavirus Antigens for Enhancing Immunogenicity.

Jung H, Jeong S, Kang M, Hong I, Park Y, Ko E Vaccines (Basel). 2024; 12(9).

PMID: 39340050 PMC: 11435836. DOI: 10.3390/vaccines12091020.

Rotavirus vaccination is a protective factor for adverse outcomes in primary intussusception: a single-center retrospective study.

Du M, Shang L, Li X, Huang R, Yao H, Yang S Transl Pediatr. 2024; 13(6):877-888.

PMID: 38984032 PMC: 11228905. DOI: 10.21037/tp-24-109.

Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco.

Mohy A, Lagoubi Y, Gomez J, Amadou B, Bouskraoui M Hum Vaccin Immunother. 2024; 20(1):2353480.

PMID: 38757507 PMC: 11110695. DOI: 10.1080/21645515.2024.2353480.

References

Chandola T, Taneja S, Goyal N, Antony K, Bhatia K, More D . ROTAVAC does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial. Heliyon. 2017; 3(5):e00302. PMC: 5435614. DOI: 10.1016/j.heliyon.2017.e00302. View

Matthijnssens J, Nakagomi O, Kirkwood C, Ciarlet M, Desselberger U, Van Ranst M . Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?. Expert Rev Vaccines. 2012; 11(11):1347-54. DOI: 10.1586/erv.12.105. View

Chen S, Tan L, Huang L, Chen K . Rotavirus infection and the current status of rotavirus vaccines. J Formos Med Assoc. 2012; 111(4):183-93. DOI: 10.1016/j.jfma.2011.09.024. View

Willame C, Vonk Noordegraaf-Schouten M, Gvozdenovic E, Kochems K, Oordt-Speets A, Praet N . Effectiveness of the Oral Human Attenuated Rotavirus Vaccine: A Systematic Review and Meta-analysis-2006-2016. Open Forum Infect Dis. 2018; 5(11):ofy292. PMC: 6284461. DOI: 10.1093/ofid/ofy292. View

Skansberg A, Sauer M, Tan M, Santosham M, Jennings M . Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1. Hum Vaccin Immunother. 2020; 17(4):1223-1234. PMC: 8018392. DOI: 10.1080/21645515.2020.1804245. View

Wang Y, Vlasova A, Velasquez D, Saif L, Kandasamy S, Kochba E . Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets. PLoS One. 2016; 11(11):e0166038. PMC: 5100943. DOI: 10.1371/journal.pone.0166038. View

Zaman K, Dang D, Victor J, Shin S, Yunus M, Dallas M . Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 376(9741):615-23. DOI: 10.1016/S0140-6736(10)60755-6. View

Patel M, Shane A, Parashar U, Jiang B, Gentsch J, Glass R . Oral rotavirus vaccines: how well will they work where they are needed most?. J Infect Dis. 2009; 200 Suppl 1:S39-48. PMC: 3673012. DOI: 10.1086/605035. View

Esposito S, Pugni L, Mosca F, Principi N . Rotarix® and RotaTeq® administration to preterm infants in the neonatal intensive care unit: Review of available evidence. Vaccine. 2017; 36(36):5430-5434. DOI: 10.1016/j.vaccine.2017.10.013. View

10.

Velazquez R, Linhares A, Munoz S, Seron P, Lorca P, DeAntonio R . Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. BMC Pediatr. 2017; 17(1):14. PMC: 5237165. DOI: 10.1186/s12887-016-0771-y. View

11.

Vesikari T, Matson D, Dennehy P, Van Damme P, Santosham M, Rodriguez Z . Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006; 354(1):23-33. DOI: 10.1056/NEJMoa052664. View

12.

Lappalainen S, Pastor A, Tamminen K, Lopez-Guerrero V, Esquivel-Guadarrama F, Palomares L . Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccin Immunother. 2014; 10(7):2039-47. PMC: 4186038. DOI: 10.4161/hv.28858. View

13.

Danchin M, Kirkwood C, Lee K, Bishop R, Watts E, Justice F . Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine. 2013; 31(23):2610-6. DOI: 10.1016/j.vaccine.2013.04.008. View

14.

Bines J, Thobari J, Satria C, Handley A, Watts E, Cowley D . Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth. N Engl J Med. 2018; 378(8):719-730. PMC: 5774175. DOI: 10.1056/NEJMoa1706804. View

15.

Safadi M, Berezin E, Munford V, Almeida F, de Moraes J, Pinheiro C . Hospital-based surveillance to evaluate the impact of rotavirus vaccination in São Paulo, Brazil. Pediatr Infect Dis J. 2010; 29(11):1019-22. DOI: 10.1097/INF.0b013e3181e7886a. View

16.

Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S . Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014; 383(9935):2136-43. PMC: 4532697. DOI: 10.1016/S0140-6736(13)62630-6. View

17.

Dhingra M, Kundu R, Gupta M, Kanungo S, Ganguly N, Singh M . Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine. 2014; 32 Suppl 1:A117-23. DOI: 10.1016/j.vaccine.2014.03.069. View

18.

Desselberger U . Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors. Pathogens. 2017; 6(4). PMC: 5750589. DOI: 10.3390/pathogens6040065. View

19.

Kawade A, Babji S, Kamath V, Raut A, Kumar C, Kundu R . Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants. Vaccine. 2019; 37(19):2554-2560. DOI: 10.1016/j.vaccine.2019.03.067. View

20.

Hemming M, Rasanen S, Huhti L, Paloniemi M, Salminen M, Vesikari T . Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr. 2013; 172(6):739-46. PMC: 7086648. DOI: 10.1007/s00431-013-1945-3. View